| Authors: |
Timofeeva N; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Herrera B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fujiwara H; Carna Biosciences, Inc., Kobe, Japan., Asami T; Carna Biosciences, Inc., Kobe, Japan., Endo H; Carna Biosciences, Inc., Kobe, Japan., Hatakeyama M; Carna Biosciences, Inc., Kobe, Japan., Nakajima F; Carna Biosciences, Inc., Kobe, Japan., Ohmoto H; Carna Biosciences, Inc., Kobe, Japan., Nishioka Y; Carna Biosciences, Inc., Kobe, Japan., Miyamoto K; CarnaBio USA Inc., South San Francisco, CA, USA., Arimura A; Carna Biosciences, Inc., Kobe, Japan.; CarnaBio USA Inc., South San Francisco, CA, USA., Tantawy SI; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Internal Medicine and Clinical Hematology Department, Suez Canal University, Ismailia, Egypt., Pinilla-Ibarz J; Moffitt Cancer Center, Tampa, FL, USA., Coombs CC; University of California, Irvine, CA, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sawa M; Carna Biosciences, Inc., Kobe, Japan., Gandhi V; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org.; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. vgandhi@mdanderson.org. |
